Physician profile
Christopher J Fyock
NPI 1073738696
$4,545.10
in general payments reported to CMS, 2019-2025
29 companies · $1,484 in 2025
The $1,484 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $81.10 · 2021: $80.09 · 2022: $694 · 2023: $954 · 2024: $646 · 2025: $1,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,052 · Education: $31.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,052.44 |
| Education | $31.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,744.58 | 2019-2025 | |
| Pfizer INC. | $327.44 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $275.05 | 2019-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $231.40 | 2019-2024 | Xifaxan, Plenvu |
| Janssen Biotech, INC. | $189.38 | 2023-2025 | Tremfya, Stelara, Simponi |
| Regeneron Healthcare Solutions, INC. | $178.91 | 2023-2025 | Dupixent |
| Madrigal Pharmaceuticals | $175.05 | 2024-2025 | Rezdiffra, Resmetirom |
| Qol Medical, LLC | $169.43 | 2019-2025 | Sucraid, Sucraid |
| Ironwood Pharmaceuticals, INC | $153.03 | 2020-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $132.31 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $114.32 | 2019-2023 | Dificid |
| Genzyme Corporation | $108.51 | 2023-2025 | |
| Celgene Corporation | $104.63 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $99.02 | 2019-2025 | Ocaliva |
| Gilead Sciences, INC. | $95.90 | 2022-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Romark Laboratories, Lc | $73.55 | 2019 | |
| Daiichi Sankyo INC. | $57.80 | 2021-2023 | Injectafer |
| Ardelyx, INC. | $57.31 | 2022-2024 | Ibsrela |
| Celltrion USA INC. | $36.12 | 2025 | Vegzelma |
| Medtronic, INC. | $31.06 | 2025 | Gi Genius |
| Redhill Biopharma INC. | $27.33 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $27.08 | 2021-2022 | |
| Boston Scientific Corporation | $27.07 | 2025 | Apollo Esg Nxt System |
| Ipsen Biopharmaceuticals, INC | $23.27 | 2024 | Iqirvo |
| Ucb, INC. | $23.19 | 2019 | |
| Alnylam Pharmaceuticals INC. | $21.74 | 2023 | Givlaari |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.15 | 2023 | |
| Ferring Pharmaceuticals INC. | $14.07 | 2024 | Rebyota |
| Organon LLC | $12.40 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Fyock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.